Three Core Aging Hallmarks Point to NAD+ and Mitophagy as Key Therapeutic Targets
A new editorial review links genomic instability, defective autophagy, and mitochondrial dysfunction to declining NAD+ — and outlines how restoring it may treat age-related disease.
Summary
Researchers from Norway, Denmark, and China examine three central hallmarks of biological aging — genomic instability, defective macroautophagy, and mitochondrial dysfunction — and argue that declining NAD+ levels connect all three. NAD+ is a critical molecule involved in DNA repair, energy metabolism, and cellular cleanup. As NAD+ falls with age, cells accumulate DNA damage, lose the ability to clear damaged components, and see mitochondrial performance deteriorate. The editorial highlights that boosting NAD+ availability — particularly by stimulating mitophagy, the process by which cells recycle damaged mitochondria — appears to be a promising therapeutic approach for conditions ranging from rare premature aging diseases like Werner syndrome to common age-related conditions like dementia and sarcopenia. The authors call for future research to clarify how these hallmarks interact and to translate laboratory findings into clinical interventions.
Detailed Summary
Understanding why we age at a molecular level is essential for developing real treatments that extend healthy lifespan. This editorial, published in Aging Medicine by leading researchers from Norway, Denmark, and the United States, takes stock of three of the most studied hallmarks of cellular aging and traces their convergence on a single, actionable molecular target.
The three hallmarks examined are genomic instability, defective macroautophagy, and mitochondrial dysfunction. Genomic instability refers to the accumulation of DNA damage that cells cannot adequately repair over time. Defective macroautophagy means the cellular recycling machinery that normally clears damaged proteins and organelles begins to fail. Mitochondrial dysfunction describes the progressive decline in the energy-producing organelles that power every cell in the body.
The central finding is that declining levels of NAD+ — the oxidized form of nicotinamide adenine dinucleotide — appears to be a shared driver connecting all three hallmarks. NAD+ is essential for DNA repair enzymes, for autophagy signaling, and for mitochondrial energy metabolism. As NAD+ falls across tissues with advancing age, each of these systems degrades in tandem.
Critically, the authors highlight that stimulating mitophagy — the selective autophagy of damaged mitochondria — through restoration of NAD+ availability looks like a particularly effective intervention point. Evidence from both laboratory models and emerging clinical data supports this pathway as therapeutically relevant for diseases including dementia, sarcopenia, Werner syndrome, and ataxia telangiectasia.
The implications are significant for clinicians and researchers alike. NAD+ precursors such as NR and NMN are already widely used as supplements, and this review strengthens the mechanistic rationale for their investigation in clinical trials targeting age-related disease. The authors note that future work must map how the hallmarks interact with each other, not just individually, and must rigorously translate findings to human therapeutic contexts. Several authors disclose commercial relationships with NAD+ supplement companies, which warrants consideration when interpreting conclusions.
Key Findings
- Declining NAD+ levels link genomic instability, defective autophagy, and mitochondrial dysfunction — three core aging hallmarks.
- Stimulating mitophagy via NAD+ restoration is identified as a promising treatment strategy for dementia and sarcopenia.
- Rare progeroid diseases like Werner syndrome and ataxia telangiectasia share molecular pathways with common age-related conditions.
- Clinical evidence is emerging to support laboratory findings that NAD+ supplementation can slow age-related cellular deterioration.
- Future research must address how aging hallmarks interact internally, not just in isolation, to guide better interventions.
Methodology
This is an editorial review article published in Aging Medicine, synthesizing existing laboratory and clinical evidence around three hallmarks of aging. It does not present new experimental data. The authors draw on decades of published research to construct a mechanistic argument linking NAD+ decline to multiple aging pathways.
Study Limitations
This summary is based on the abstract only, as the full text was not available for review. The article is an editorial review, not a primary research study, so no new experimental data are presented. Several authors have disclosed financial relationships with companies commercializing NAD+ supplements, representing a meaningful conflict of interest that may influence interpretation and emphasis.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: